– Approval Based on Phase 3 PURPOSE 1 and PURPOSE 2 Data that Showed ≥99.9% of Participants Remained HIV Negative on Twice-Yearly Injectable Yeztugo – – Yeztugo, Nearly 20 Years in the Making, ...

– Gilead’s Research Presentations and Community Events at IAS Reflect Commitment to Partnerships in Developing Person-Centered Options for a Diverse Range of Populations – FOSTER CITY, ...

The FDA just approved the first and only HIV prevention shot you only need twice a year. That means powerful, long-acting ...

Gilead partners with PEPFAR to deliver twice-yearly lenacapavir for HIV prevention for up to two million people in LLMICs: Foster City, California Saturday, September 6, 2025, 11: ...

Scientists at Merck & Co. have unveiled the structure of the company’s latest candidate for HIV pre-exposure prophylaxis ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted marketing authorization for Yeytuo® (lenacapavir)—the company’s twice-yearly injectable HIV-1 capsid ...

Gilead will supply enough lenacapavir to reach 2M people in Global Fund-supported nations over three years at no profit. Yeztugo, priced at $28,218 annually in the U.S., is the only twice-yearly PrEP ...

Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Yeztugo® (lenacapavir)—the company’s ...

– New Data from PURPOSE Trials Further Demonstrate that Lenacapavir (Yeztugo ®) was Effective and Well Tolerated Across a Broad Range of Populations, Including Pregnant and Lactating Women, ...

Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.